Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl₄-Induced Liver Fibrosis in Rats.

ABSTRACT: Hepatic fibrosis (HF) is a major cause of liver-related disorders and together with cancer-associated fibroblasts can favor liver cancer development by modulating the tumor microenvironment. Advanced HF, characterized by an excess of extracellular matrix (ECM), is mediated by TGF- β1, that activates hepatic stellate cells (HSCs) and fibroblasts. A TGF-β1 receptor inhibitor, LY2157299 or Galunisertib (GLY), has shown promising results against chronic liver progression in animal models, and we show that it can be further improved by enhancing GLYs bioavailability through encapsulation in polymeric polygalacturonic-polyacrylic acid nanomicelles (GLY-NMs). GLY-NMs reduced HF in an in vivo rat model of liver fibrosis induced by intraperitoneal injection of CCl₄ as shown by the morpho

SUBMITTER: Panzarini E 

PROVIDER: S-EPMC9692463 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature